This HTML5 document contains 122 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/pubchem-compound/
n23http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/national-drug-code-directory/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n25http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00438/identifier/chebi/
n18http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00438
rdf:type
n5:Drug
n5:description
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients. [PubChem]
n5:dosage
n15:271B4EC4-363D-11E5-9242-09173F13E4C5 n15:271B4EC5-363D-11E5-9242-09173F13E4C5 n15:271B4EC6-363D-11E5-9242-09173F13E4C5 n15:271B4EC7-363D-11E5-9242-09173F13E4C5 n15:271B4EC8-363D-11E5-9242-09173F13E4C5 n15:271B4EC9-363D-11E5-9242-09173F13E4C5 n15:271B4ECA-363D-11E5-9242-09173F13E4C5 n15:271B4ECB-363D-11E5-9242-09173F13E4C5 n15:271B4ECC-363D-11E5-9242-09173F13E4C5 n15:271B4ECD-363D-11E5-9242-09173F13E4C5 n15:271B4ECE-363D-11E5-9242-09173F13E4C5 n15:271B4ECF-363D-11E5-9242-09173F13E4C5 n15:271B4ED0-363D-11E5-9242-09173F13E4C5 n15:271B4ED1-363D-11E5-9242-09173F13E4C5 n15:271B4ED2-363D-11E5-9242-09173F13E4C5 n15:271B4ED3-363D-11E5-9242-09173F13E4C5 n15:271B4EC1-363D-11E5-9242-09173F13E4C5 n15:271B4EC2-363D-11E5-9242-09173F13E4C5 n15:271B4EC3-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.
n5:indication
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
n5:manufacturer
n8:271B4EAD-363D-11E5-9242-09173F13E4C5 n8:271B4EAE-363D-11E5-9242-09173F13E4C5 n8:271B4EAB-363D-11E5-9242-09173F13E4C5 n8:271B4EAC-363D-11E5-9242-09173F13E4C5 n8:271B4EA9-363D-11E5-9242-09173F13E4C5 n8:271B4EAA-363D-11E5-9242-09173F13E4C5 n8:271B4EAF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00438 n24:DB00438
dcterms:title
Ceftazidime
adms:identifier
n4:DB00438 n7:3508 n9:4587145 n11:5481173 n12:46506143 n13:PA448861 n14:Ceftazidime n26:C06889 n27:25021-127-20
n5:mechanismOfAction
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
n5:packager
n8:271B4EA7-363D-11E5-9242-09173F13E4C5 n8:271B4EA8-363D-11E5-9242-09173F13E4C5 n8:271B4EA1-363D-11E5-9242-09173F13E4C5 n8:271B4EA2-363D-11E5-9242-09173F13E4C5 n8:271B4E9F-363D-11E5-9242-09173F13E4C5 n8:271B4EA0-363D-11E5-9242-09173F13E4C5 n8:271B4EA5-363D-11E5-9242-09173F13E4C5 n8:271B4EA6-363D-11E5-9242-09173F13E4C5 n8:271B4EA3-363D-11E5-9242-09173F13E4C5 n8:271B4EA4-363D-11E5-9242-09173F13E4C5 n8:271B4E9E-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.
n5:synonym
Ceftazidima Ceftazidim Ceftazidime Ceftazidimum Ceftazidime anhydrous (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate CAZ
n5:toxicity
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
n17:hasAHFSCode
n19:08-12-06-12
n5:proteinBinding
< 10%
n5:salt
n5:synthesisReference
Ronald C. Browning, Melvin G. Pleiss, Jr., "Crystallization process for ceftazidime derivative." U.S. Patent US4659813, issued May, 1982.
foaf:page
n21:ceftazidime.html n25:ceftaz.htm
n5:IUPAC-Name
n6:271B4ED8-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4EDE-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4EDD-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4EDA-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4EDB-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4EDC-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4ED6-363D-11E5-9242-09173F13E4C5 n6:271B4EEE-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4ED4-363D-11E5-9242-09173F13E4C5 n6:271B4ED7-363D-11E5-9242-09173F13E4C5 n6:271B4EF0-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4ED5-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:J01DD02
n5:H-Bond-Acceptor-Count
n6:271B4EE4-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4EE5-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4EDF-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4EE0-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4EE2-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4EE1-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4EE3-363D-11E5-9242-09173F13E4C5
n5:absorption
The absorption of ceftazidime is directly proportional to the size of the dose.
n5:affectedOrganism
Enteric bacteria and other eubacteria
n5:casRegistryNumber
78439-06-2
n5:category
n5:clearance
* 115 mL/min
n5:containedIn
n16:271B4EBF-363D-11E5-9242-09173F13E4C5 n16:271B4EC0-363D-11E5-9242-09173F13E4C5 n16:271B4EB0-363D-11E5-9242-09173F13E4C5 n16:271B4EBB-363D-11E5-9242-09173F13E4C5 n16:271B4EBE-363D-11E5-9242-09173F13E4C5 n16:271B4EBC-363D-11E5-9242-09173F13E4C5 n16:271B4EBD-363D-11E5-9242-09173F13E4C5 n16:271B4EB1-363D-11E5-9242-09173F13E4C5 n16:271B4EB2-363D-11E5-9242-09173F13E4C5 n16:271B4EB5-363D-11E5-9242-09173F13E4C5 n16:271B4EB6-363D-11E5-9242-09173F13E4C5 n16:271B4EB3-363D-11E5-9242-09173F13E4C5 n16:271B4EB4-363D-11E5-9242-09173F13E4C5 n16:271B4EB9-363D-11E5-9242-09173F13E4C5 n16:271B4EBA-363D-11E5-9242-09173F13E4C5 n16:271B4EB7-363D-11E5-9242-09173F13E4C5 n16:271B4EB8-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B4EEA-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4EEC-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4EED-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4EEF-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4EE9-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4EE8-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4EEB-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4ED9-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4EE6-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4EE7-363D-11E5-9242-09173F13E4C5